Anzeige
Mehr »
Mittwoch, 05.11.2025 - Börsentäglich über 12.000 News
SuperBuzz explodiert um 20% nach Mega-Deal mit NASDAQ-Werberiesen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
44 Leser
Artikel bewerten:
(0)

Centaur Animal Health Announces Addition to Board of Directors

KANSAS CITY, Kan. and PHILADELPHIA, Feb. 28, 2014 /PRNewswire-USNewswire/ --Centaur Animal Health, an animal therapeutics company focused on the licensing, acquisition, development and commercialization of innovative technologies from animal health or human pharmaceutical and biotechnology companies, announced an addition to its Board of Directors.The Board has appointed Dr. Thomas Overbay, DVM, Partner at Expedite, a privately held animal health consulting firm.

Developing innovative diagnostics, pharmaceuticals and nutraceuticals that address significant therapeutic needs for companion and production animals.

Mark Metrokotsas, Chairman of the Board of Centaur Animal Health, stated, "We are pleased to welcome Tom Overbay to our Board. We expect to benefit from Dr. Overbay's strong background in the animal health industry."

Jeffrey Boily, President and Chief Executive Officer of Centaur Animal Health, stated, "As Centaur continues to grow, we are pleased to enhance our Board with the knowledge and experience Dr. Overbay brings from his 30 years in the animal health industry."

Prior to forming Expedite, Dr. Overbay has served as the senior business development officer for a major animal health company and has served in similar roles with a contract services provider and start-up animal health companies in the US and internationally. In addition to business development, Dr. Overbay's background of veterinary practice, technical services, and sales management provides him with a unique perspective of the scientific, financial, and legal aspects of innovative technologies. Dr. Overbay has successfully brought to market a number of products arising from universities, government agencies, human hospitals, start-up companies (both human and veterinary), and multinational pharmaceutical and chemical companies. Dr. Overbay holds a veterinary degree from the Virginia-Maryland Regional College of Veterinary Medicine and resides in Louisburg, Kansas.

About Centaur Animal Health
Centaur Animal Health is focused on developing innovative diagnostics, pharmaceuticals and nutraceuticals that address significant therapeutic needs for companion and production animals. Centaur licenses patent-protected technologies acquired from animal health or human pharmaceutical and biotechnology companies. Contract manufacturing is available in their FDA, DEA and USDA certified plant. For more information, please visit www.centauranimalhealth.com

About Expedite, LLC
Expedite, LLC is a contract business development provider to the animal health industry. Expedite serves in a variety of roles including technology prospecting, technology assessment, and design of development strategies for biologicals, pharmaceuticals, and ectoparasiticides among other animal health products for commercialization around the world. In these capacities, Expedite clients range from multinational animal health companies, startup companies, investment organizations, and human health companies seeking to enter or expand their role in the global animal health industry. For more information on Expedite, please contact toverbay@expediteanimalhealth.com.

For Media: Ashley Hayes
Centaur Animal Health
O: (913) 390-6184
ashley.hayes@centauranimalhealth.com
Web Site: http://www.centauranimalhealth.com

Logo -http://photos.prnewswire.com/prnh/20140228/DC74598LOGO

SOURCE Centaur Animal Health

© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.